What is the recommended treatment for decreased DLCO in a patient?

• A. Antibiotics
• B. Bronchodilators
• C. Steroids
• D. Inhaled corticosteroids

Answer: (C)

In cases where a patient presents with a decreased diffusing capacity of the lungs for carbon monoxide (DLCO), which can occur in a variety of pulmonary conditions, the administration of corticosteroids may be appropriate to address underlying inflammatory processes. Conditions that result in reduced DLCO often include interstitial lung diseases or autoimmune disorders affecting the lungs. Corticosteroids are effective in reducing inflammation and can help improve lung function and gas exchange.

Despite other treatments being important in specific situations, they may not be directly beneficial for addressing the issue of decreased DLCO. For example, antibiotics would not treat the underlying lung pathology associated with decreased DLCO unless there is a specific infectious process involved. Bronchodilators primarily work by relaxing the muscles around the airways and may help with airway obstruction but do not specifically target the diffusion capacity. Inhaled corticosteroids are often used in asthma or chronic obstructive pulmonary disease situations to reduce inflammation in the airways, but oral or systemic corticosteroids tend to be more effective in managing broad inflammatory processes associated with a decrease in DLCO.

Thus, corticosteroids are considered a rational choice for managing conditions with reduced DLCO stemming from inflammation or autoimmune activity in the lungs.